| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Division of Biomathematics [J. A. K., A. C. F.] and W. M. Keck Autoimmune Disease Center, Department of Molecular and Experimental Medicine [J-Y. Z., F-D. S., E. K. L. C., E. M. T.], The Scripps Research Institute, La Jolla, California; Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas [J-Y. Z.]; Department of Biochemistry and Microbiology, Center for Molecular Biology and Gene Therapy, Loma Linda University School of Medicine, Loma Linda, California [C. A. C.]; Department of Biology, School of Life Sciences, Xiamen University, Xiamen, People’s Republic of China [X-X. P.]; and Department of Oral Biology, University of Florida Health Sciences Center, Gainesville, Florida [E. K. L. C.]
ABSTRACT
Purpose and Experimental Design: Cancer sera contain antibodies which react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), but the low frequency of positive reactions against any individual antigen has precluded use of autoantibodies as useful diagnostic markers. With enzyme immunoassay, we examined antibody frequencies to a panel of seven TAAs, c-myc, cyclin B1, IMP1, Koc, p53, p62, and survivin, in 527 cancer patients (64 breast cancer patients, 45 colorectal cancers, 91 gastric cancers, 65 hepatocellular carcinomas, 56 lung cancers, and 206 prostate cancers), and 346 normals. We used recursive partitioning to assess whether we could accurately classify individuals as either cancer patients or normals on the basis of the profile of antibody reactivity to the seven TAAs for each individual.
Results: Recursive partitioning resulted in the selection of subsets of the seven-panel TAA, which differentiated between tumors and controls, and these subsets were unique to each cancer cohort. The classification trees had sensitivities ranging from 0.77 to 0.92 and specificities ranging from 0.85 to 0.91 in the cancer cohorts when normal means +2 SDs were used as standard cutoffs for immunoassay positivity. Antibody to cyclin B1 was the initial discriminating node for gastric and lung cancers, and for hepatocellular carcinoma, and was a subsequent discriminating node in all of the other cancer cohorts. c-myc was the initial discriminating node in breast cancer, p62 in prostate cancer, and IMP1 in colon cancer. Recursive partitioning demonstrated that no more than three of the seven TAAs were needed for any cancer cohort to arrive at these levels of sensitivity and specificity.
Conclusions: This initial study shows that multiple antigen miniarrays can provide accurate and valuable tools for cancer detection and diagnosis. Performance of the miniarrays might be enhanced by other combinations of TAAs appropriately selected for different cancer cohorts.
This article has been cited by other articles:
|
|
 |
|
  V. Goodell, J. Waisman, L. G. Salazar, C. dela Rosa, J. Link, A. L. Coveler, J. S. Childs, P. A. Fintak, D. M. Higgins, and M. L. Disis Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity Mol. Cancer Ther., March 1, 2008; 7(3): 449 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gagnon, J.-H. Kim, J. O. Schorge, B. Ye, B. Liu, K. Hasselblatt, W. R. Welch, C. A. Bandera, and S. C. Mok Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 764 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, X. Wang, J. Yu, S. Varambally, J. Yu, D. G. Thomas, M.-Y. Lin, P. Vishnu, Z. Wang, R. Wang, et al. Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma Cancer Res., April 1, 2007; 67(7): 3461 - 3467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cleynen, J. R. Brants, K. Peeters, R. Deckers, M. Debiec-Rychter, R. Sciot, W. J.M. Van de Ven, and M. M.R. Petit HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-{kappa}B Mol. Cancer Res., April 1, 2007; 5(4): 363 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Chen, S.-L. Yu, C.-H. Chen, G.-C. Chang, C.-Y. Chen, A. Yuan, C.-L. Cheng, C.-H. Wang, H.-J. Terng, S.-F. Kao, et al. A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer N. Engl. J. Med., January 4, 2007; 356(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Erkanli, D. D. Taylor, D. Dean, F. Eksir, D. Egger, J. Geyer, B. H. Nelson, B. Stone, H. A. Fritsche, and R. B.S. Roden Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection Cancer Res., February 1, 2006; 66(3): 1792 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Egloff, L. A. Vella, and O. J. Finn Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer Cancer Res., January 1, 2006; 66(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M. Tan, J. A. Koziol, Y. Kida, M. A. Thorat, R. A. Badwe, B. Rocco, B. Djavan, O. de Cobelli, X. Wang, D. Ghosh, et al. Autoantibodies in prostate cancer. N. Engl. J. Med., December 29, 2005; 353(26): 2815 - 2817. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. EGLOFF, J. WEISSFELD, S. R. LAND, and O. J. FINN Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung Cancer Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 29 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-w. Cui, W.-h. Li, J. Wang, A.-l. Li, H.-y. Li, H.-x. Wang, K. He, W. Li, L.-h. Kang, M. Yu, et al. Proteomics-based Identification of Human Acute Leukemia Antigens That Induce Humoral Immune Response Mol. Cell. Proteomics, November 1, 2005; 4(11): 1718 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Finn Immune Response as a Biomarker for Cancer Detection and a Lot More N. Engl. J. Med., September 22, 2005; 353(12): 1288 - 1290. [Full Text] [PDF]
|
|
|
|
|
|
H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn T Cell-Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease Clin. Cancer Res., February 15, 2005; 11(4): 1521 - 1526. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
